(PharmaNewsWire.Com, November 25, 2021 ) The companion animal diagnostics market is projected to reach USD 3.0 billion by 2025 from USD 1.8 billion in 2020, at a CAGR of 9.8%. The growth in this market is driven by growth in the companion animal population, rising demand for pet insurance, and increasing number of veterinary practitioners in developed economies. The growing demand for rapid tests and portable instruments for point-of-care services is expected to offer potential growth opportunities for market players in the coming years.
The molecular diagnostics segment is expected to grow at the highest CAGR during the forecast period Based on technology, the companion animal diagnostics market is segmented into clinical biochemistry, immunodiagnostics, hematology, urinalysis, molecular diagnostics, and other companion animal diagnostic technologies. The molecular diagnostics segment is expected to grow at the highest CAGR during the forecast period. The need for reliable, specific, and faster methods to detect chronic diseases and genetic disorders in the early stages is expected to drive the molecular diagnostics market for companion animal diagnostics.
Clinical pathology segment to dominate the companion animal diagnostics market during the forecast period Based on application, the market is segmented into clinical pathology, bacteriology, virology, parasitology, and other applications. The clinical pathology segment is estimated to account for the largest share of the market during the forecast period. The clinical pathology tests are considered as the first tool for the evaluation of disease patterns as it provides an understanding of disease mechanism and progression, which is important for the development of new treatments.
Asia Pacific market to witness the highest growth during the forecast period The global companion, animal diagnostics market, is segmented into five major regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. In 2019, North America was estimated to be the largest regional market for companion animal diagnostics. However, the Asia Pacific market is expected to grow at the highest CAGR during the forecast period primarily due to factors such as growth in pet adoption, increasing awareness about animal health, and increasing per capita animal health expenditure, especially in India and China.
Key Market Players IDEXX Laboratories, Inc. (US), and Zoetis, Inc. (US) and Heska Corporation (US) are the major players operating in the companion animal diagnostics market. Some of the other players operating in this market are Thermo Fisher Scientific, Inc. (US), Virbac (France), Heska Corporation (US), Neogen Corporation (US), bioMérieux SA (France), IDvet (France), INDICAL Bioscience GmbH (Germany) [QIAGEN N.V. (Netherlands)], and Randox Laboratories Ltd. (UK).
IDEXX Laboratories was the leading player in the market and accounted for the largest share of 55-60% in 2019. The company has a diversified product portfolio, which includes a wide range of companion animal diagnostic products. IDEXX’s position in the market is attributed to its active R&D activities and wide distribution footprint across the world. It enables the company to serve customers in more than 100 countries. To garner a larger share in the market, the company continuously focuses on product developments and launches. For instance, in January 2019, the company launched Canine Progesterone Test for Catalyst Dx and Catalyst One analyzers for the canines. Similarly, in January 2018, IDEXX launched its IDEXX Catalyst SDMA Test to analyze kidney function in companion animals.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including: